Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma

Area of Science:

• Oncology
• Immunology
• Microbiome research

Background:

• Metastatic renal cell carcinoma (mRCC) treatment with immune checkpoint inhibitors or tyrosine kinase inhibitors can lead to resistance.
• Gut dysbiosis disrupts the MAdCAM-1-α4β7 axis, promoting immunosuppressive T regulatory cells (Tr17) in tumors.
• Identifying reliable prognostic biomarkers is crucial for optimizing mRCC treatment strategies.

Purpose of the Study:

• To evaluate soluble MAdCAM-1 (sMAdCAM-1) as a prognostic biomarker in patients with mRCC.
• To assess the association between sMAdCAM-1 levels and treatment outcomes across different therapeutic regimens.
• To explore the relationship between sMAdCAM-1 levels and gut microbiota composition.

Main Methods:

• Analysis of 1,051 patients from three independent cohorts (JAVELIN Renal 101, SURF, NIVOREN).
• Measurement of baseline soluble MAdCAM-1 (sMAdCAM-1) levels.
• Correlation of sMAdCAM-1 levels with progression-free survival (PFS) and overall survival (OS).
• Gut microbiota profiling in relation to sMAdCAM-1 levels.

Main Results:

• In the JAVELIN cohort, elevated baseline sMAdCAM-1 (>180 ng/mL) was significantly associated with improved PFS (13.9 vs. 8.4 months) and OS (84.2% vs. 68.1% at 18 months).
• The prognostic value of sMAdCAM-1 for OS was validated in the SURF and NIVOREN cohorts.
• Low sMAdCAM-1 levels correlated with an immunosuppressive gut microbiota profile, particularly enrichment of Enterocloster species.

Conclusions:

• Soluble MAdCAM-1 (sMAdCAM-1) demonstrates significant prognostic value for survival in mRCC patients treated with immunotherapy or targeted therapy.
• sMAdCAM-1 may serve as a valuable biomarker for guiding microbiota-targeted interventions in mRCC.
• Further investigation of sMAdCAM-1 is warranted for its potential role in personalized mRCC treatment.